StockNow
Calendar
Log in
U.S. Markets

Merck’s (MRK) Keytruda as monotherapy reduced the risk of disease progression or death by 43% vs chemotherapy for certain patients with advanced or recurrent endometrial cancer with mismatch repair deficient tumours

StockNow breaking-news AI analysis

The headline reports a 43% reduced risk of progression or death with Keytruda monotherapy versus chemotherapy in certain patients; study details are unavailable.

1 stocks
MRKMerck & Co., Inc.$141.01Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
U.S. Markets

Anthropic files for IPO; applied to list Class A common stock on Nasdaq Global select market under the symbol 'ANT'

GSMSJPMGeopolitics

Senior Iranian official says talks in Tehran with Mecca Pact members exclude the nuclear issue, reports suggest; Iran will not discuss its nuclear programme until the US meets Tehran's demands

Geopolitics

An explosion has reportedly occurred aboard a vessel off the coast of Iraq, amid reports of an attack, Fars reports